Momenta Pharmaceuticals Stock Company Profile

Description

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and M356, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. The company’s novel therapeutics programs include Necuparanib, a novel oncology product candidate derived from heparin; Anti-FcRn program for acute and chronic/intermittent therapies in a range of autoantibody driven diseases; SIF3 program, a novel recombinant protein containing three IgG Fc regions to maximize activity; and hsIVIg, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, Baxalta U.S. Inc., Baxalta GmbH, and Baxalta Incorporated. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.